SLE Clinical Trial - Serum IL 26 as a Marker of Disease Activity in SLE

Status Not yet recruiting

Clinical Trial Summary

Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity.

Clinical Trial Description

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by diverse autoantibodies and varied clinical manifestations(mainly targeting the skin, kidneys, and brain). Autoantibodies directed against double-stranded (ds) DNA play a key role in the initiation and maintenance of inflammatory lesions in SLE(1). Pathogenesis of SLE is mirrored by its complex aetiopathogenesis as genetic factors , environmental triggers (exposure to sunlight, drugs and infections, particularly with Epstein-Barr virus. . Causing secretion of inflammatory mediators , antibody and cytokines . But still pathological mechanisms of SLE are still not fully understood. (2) Immune system dysregulation such as incomplete clearance of apoptotic materials, hyperactivation of immune cells, overproduction of antibodies and abundant immune complex deposits are prominent in SLE (3) Clinical manifestations of SLE are Malar rash, Discoid rash ,Photosensitivity, Oral or nasopharyngeal ulcers, Pleurisy, Renal abnormalities, Immunologic abnormalities, Nonscarring alopecia, Synovitis, Hemolytic anemia, Leukopenia, Thrombocytopenia Proteinuria Seizures Psychosis Serositis and Arthritis (4) IL-26 is a 171-amino acid protein that belongs to the IL-10 family of cytokines, a family that includes IL-10, IL-19, IL-20, IL-22 and IL-24 . The IL-26 protein is encoded by the IL26 gene located on chromosome 12q15 between genes for interferon (IFN)-γ and IL-22 , and is conserved in several vertebrate species but not in mice and rats . The cytokine IL-26 was originally named AK155(5) IL-26 was initially identified as a pro-inflammatory cytokine , inducing the production of inflammatory cytokines by myeloid cells that are involved in the differentiation of naïve CD4+ T cells into Th17 cells (6) The involvement of IL 26 in numerous chronic auto inflammatory diseases and in two major pathogenic processes in SLE, namely the induction of IFN I and its production by Th 17 lymphocytes, makes the analysis of its role in SLE essential (7) Brilland et al., 2021 report that the levels of IL 26 are higher in SLE patients than healthy subjects and show a significant correlation with disease activity ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05161988
Study type	Observational
Source	Assiut University
Contact	Fatma Al-zahraa M. Abdel-bary, resident
Phone	0201014363853
Email	Zahraamustafa22@yahoo.com
Status	Not yet recruiting
Phase
Start date	December 10, 2021
Completion date	May 1, 2025

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT05479071` - Relation of Antibodies Against Oxidized Low Density Lipoproteins to Disease Activity and Cardiovascular Affection in Systemic Lupus.
Completed	`NCT02240888` - Vaccination in Inflammatory Rheumatic Disease (VACCIMIL). The Impact of Antirheumatic Treatment on Antibody Response	N/A
Active, not recruiting	`NCT05748925` - Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients	Phase 4
Not yet recruiting	`NCT04517240` - A Study on Protein Losing Enteropathy In Systemic Lupus Erythematosus
Completed	`NCT00710021` - Vitamin D3 in Systemic Lupus Erythematosus	Phase 2
Terminated	`NCT01946880` - Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)	Phase 2
Active, not recruiting	`NCT04018222` - Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic
Completed	`NCT03240536` - Choosing Tests Wisely in Rheumatology	N/A
Completed	`NCT04368299` - Telemedicine for Follow-up of Systemic Lupus Erythematosus	N/A
Active, not recruiting	`NCT04037293` - Premature Atherosclerosis in Systemic Lupus Erythematosus
Not yet recruiting	`NCT04234633` - Effect of Gender on Clinical Presentation of SLE ِAt Assiut University Hospitals
Completed	`NCT01207297` - Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis	Phase 1
Terminated	`NCT00152555` - Physical Therapy for Systemic Lupus Erythematosus (SLE)	N/A
Recruiting	`NCT05822219` - Vaccine Hesitancy in Black/African Americans With Rheumatic Diseases	N/A
Completed	`NCT04806113` - COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases	Phase 3
Recruiting	`NCT05966480` - Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus	Phase 2
Completed	`NCT03155477` - Effect Of Curcuma Xanthorrhiza and Vitamin D3 Supplementation in SLE Patients With Hypovitamin D	N/A
Recruiting	`NCT05342285` - Flow Mediated Dilation in Association With Hyperuricemia
Not yet recruiting	`NCT03984227` - New Signaling Pathway Targeting Systemic Lupus Erythematosus
Enrolling by invitation	`NCT03144063` - Improving the Assessment of SLE Disease Activity	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.